Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma-Reference-Cited by-同舟云学术

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma

Published:2010-10 Issue:2 Volume:89 Page:175-181
ISSN:0014-4800
Container-title:Experimental and Molecular Pathology
language:en
Short-container-title:Experimental and Molecular Pathology

Author:

Pabst Caroline,Zustin Jozef,Jacobsen Frank,Luetkens Tim,Kröger Nicolaus,Schilling Georgia,Bokemeyer Carsten,Sauter Guido,Atanackovic Djordje,Marx Andreas

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Molecular Biology,Pathology and Forensic Medicine

Reference37 articles.

1. Multiple myeloma: a review of the epidemiologic literature;Alexander;Int. J. Cancer,2007

2. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens;Almeida;Nucleic Acids Res.,2009

3. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation;Atanackovic;Blood,2007

4. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells;Atanackovic;Haematologica,2010

5. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma;Atanackovic;Clin. Cancer Res.,2009

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutational signatures and their association with survival and gene expression in urological carcinomas;Neoplasia;2023-10

2. Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients;Cancers;2022-04-29

3. Emerging roles of the MAGE protein family in stress response pathways;Journal of Biological Chemistry;2020-11

4. MAGE genes: Prognostic indicators in AL amyloidosis patients;Journal of Cellular and Molecular Medicine;2019-06-20

5. Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma;American Journal of Clinical Oncology;2019-03